Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
0.3%
Period ended Dec 31, 2025
Change on a year earlier
+0.9 pts
-0.6% in Q4 2024
History
11 quarters
Since Q2 2023
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 0.3% | +0.9 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 0.4% | +1.8 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 0.1% | +1.6 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -1.2% | -0.4 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | -0.6% | -0.5 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | -1.4% | -1.1 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -1.5% | -1.0 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -0.8% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -0.1% | – | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -0.3% | – | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | -0.5% | – | SEC Filing (0001628280-23-025156) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%) (%), quarterly Q2 2023–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-fx
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.